Our Portfolio

Direct Investments

We take an active role in our portfolio companies, contributing expertise in drug discovery, development and operations, to help them deliver maximum patient value.


AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio

01 Mar 2022. AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio

 SpliceBio Raises EUR 50M in Oversubscribed Series A financing to Advance Protein Splicing Platform and Expand Gene Therapy Pipeline

16 Feb 2022. SpliceBio Raises EUR 50M in Oversubscribed Series A financing to Advance Protein Splicing Platform and Expand Gene Therapy Pipeline

EsoBiotec is a biotechnology company developing an in vivo engineering platform to produce cancer fighting cells inside the patient’s body.

15 Dec 2021. EsoBiotec

Neurona is a cell therapy company focused on the development of breakthrough treatments for neurological disorders

19 Apr 2021. Neurona Therapeutics Presents Preclinical Data from Lead Cell Therapy Program, Demonstrating Significant Seizure Suppression in Model of Focal Epilepsy

Walden Biosciences, Inc., a biotechnology company focused on transforming the treatment of kidney disease.

06 Oct 2020. Walden seeking to develop breakthrough medicines to reverse kidney disease progression.

StrideBio, Inc. is a gene therapy company focused on creating and developing novel adeno-associated viral (AAV) vector technologies.

16 Mar 2021. StrideBio Announces Closing of $81.5M Series B Financing
14 Nov 2019. Sarepta and StrideBio Announce Multi-target Collaboration to Advance Novel Gene Therapies

Rinri Therapeutics is a biotechnology company developing advanced stem cell-based therapeutics to treat hearing loss.

20 May 2019. Rinri Therapeutics secures £1.4 million seed funding to advance its novel regenerative cell therapy to treat sensorineural hearing loss

Locana, Inc. is an RNA-targeting gene therapy company with a platform technology to address a wide spectrum of human genetic diseases.

14 Dec 2020. Locanabio Announces $100 Million Series B Financing to Advance Portfolio of Novel RNATargeted Gene Therapies for Neurodegenerative, Neuromuscular and Retinal Diseases
10 Dec 2019. Locana Expands Leadership Team with Appointment of former Casebia CEO as Chief Executive Officer

Ally Therapeutics

Ally Therapeutics is a gene therapy company spun out of Harvard.

31 Jul 2019. Ally secured seed finance from ARCH Venture Partners, Alta Partners and UCB Ventures to advance its novel gene therapy platform.

Syndesi Therapeutics is developing novel modulators of the synaptic vesicle protein SV2A to address disorders of cognition.

27 Jan 2021. Syndesi Therapeutics announces positive results from two additional Phase I studies of its novel SV2A modulator SDI-118, providing strong support for the initiation of further clinical trials in cognitive impairment
19 Dec 2019. Syndesi Therapeutics announces the expansion of its management team with the appointment of Torsten Madsen, MD, PhD as Chief Medical Officer.

ExeVir Bio is an VHH antiviral platform company focused on rapid control with a lead compound for COVID-19.

15 Mar 2021. ExeVir Announces Close of US$50 million / EUR42 million Series A Financing
28 Jul 2020. ExeVir Bio to Accelerate Development of New Treatment Conferring Broad Protection Against Covid-19

Selected Invested Funds


arixbioscience.com Arix Bioscience supports medical innovation at all stages of development and has access to breakthrough academic science.


aPappas is dedicated to furthering life science discoveries and delivering groundbreaking solutions to market.


Qiming drives innovation and growth of business enterprises and promotes overall industry advancement and social development.